

Andrea Kuhn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4766361/publications.pdf>

Version: 2024-02-01

10
papers

237
citations

1477746

6
h-index

1473754

9
g-index

10
all docs

10
docs citations

10
times ranked

468
citing authors

#	ARTICLE	IF	CITATIONS
1	Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. British Journal of Haematology, 2020, 190, e279-e282.	1.2	89
2	A national service for delivering CD19 CAR-T in large B-cell lymphoma – The UK real-world experience. British Journal of Haematology, 2022, 198, 492-502.	1.2	40
3	Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. Blood Advances, 2022, 6, 321-326.	2.5	37
4	Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England. Blood, 2019, 134, 767-767.	0.6	27
5	Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. Blood Advances, 2022, 6, 2920-2926.	2.5	20
6	CAR-T Toxicity Management and Steroid Use in High-Grade B-Cell Lymphoma: Impact on Real-World Survival Outcomes in the UK. Blood, 2021, 138, 531-531.	0.6	8
7	Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucef Treatment for Refractory Diffuse Large B Cell Lymphoma. HemaSphere, 2021, 5, e535.	1.2	7
8	Colitis After CAR T-Cell Therapy for Refractory Large B-Cell Lymphoma Responds to Anti-Integrin Therapy. Inflammatory Bowel Diseases, 2021, 27, e45-e46.	0.9	5
9	Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis. Leukemia and Lymphoma, 2022, 63, 1980-1984.	0.6	4
10	Chimeric antigen receptor T-cell toxicities – using steroids to spare steroids?. British Journal of Haematology, 2021, 194, 659-660.	1.2	0